Bullish case
$28 to $30
More likely if Healthpeak delivers positive same-store NOI growth, lab occupancy improves, Janus Living compounds without excess leverage, and REIT multiples expand as rates fall.
Healthpeak Properties, Inc. research snapshot
DOC AI Stock Analysis
DOC AI stock analysis currently reads Healthpeak Properties as a healthcare REIT with improving outpatient medical execution, a recovering lab outlook, senior housing optionality through Janus Living, and a meaningful dividend yield. The AI view is not a single price prediction: the business quality is supported by healthcare real estate demand and recurring rental income, while the entry price depends on interest rates, lab leasing recovery, leverage discipline, and whether FFO growth can support the current dividend and valuation.
Current price
$21.93
Market cap
$15.12 billion
AI score
67 / 100
Rating
Income REIT, valuation watch
Trend status
Constructive near 52-week highs, rate-sensitive
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Healthpeak is an S&P 500 REIT with SEC filings, quarterly supplemental reports, investor releases, analyst coverage, and public market data.
- bias Check
- The main AI research risk is over-relying on headline EPS for a REIT. This page separates GAAP EPS from FFO, AFFO, leverage, dividend coverage, same-store NOI, and capital recycling.
- ai Confidence
- High for reported revenue, FFO, dividend, share count, and market data. Medium for forecast ranges because rates, private real estate values, lab demand, and Janus Living execution can change quickly.
- investment Certainty
- Medium. The property base and dividend profile are understandable, but valuation and downside risk remain tied to interest rates, tenant demand, leverage, and capital market access.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Healthpeak owns healthcare discovery and delivery real estate across outpatient medical, lab, and senior housing-related assets. | Medium-high |
| Moat | The moat comes from location, healthcare system relationships, scale, leasing capability, and specialized property operations rather than classic brand pricing power. | Medium |
| Management | Management is actively recycling capital, buying back stock below estimated asset value, forming Janus Living, and integrating the Physicians Realty platform. | Medium-high |
| Financial trend | FY2025 revenue was about $2.82 billion, FY2025 FFO as Adjusted was $1.84 per share, and Q1 2026 FFO as Adjusted was $0.45 per share. | High |
| Valuation | At $21.93, DOC trades near 12.7x a $1.73 FFO-style cash earnings proxy and offers a dividend yield near 5.56%. | Medium |
| Technical trend | The stock is near its 52-week high and above key moving averages, but RSI readings show momentum can be extended. | Medium |
| Risk level | Risk is moderate for an income REIT: leverage, rates, lab leasing, tenant credit, development costs, and Janus Living exposure matter. | Medium-high |
| AI confidence | The data set is deep, but REIT analysis depends on non-GAAP measures and property-level assumptions that require judgment. | High data confidence |
| Investment certainty | The dividend and asset base are visible, but the margin of safety is thinner when the stock trades near recent highs. | Medium |
DOC AI stock forecast
DOC AI Stock Forecast Scenarios
The DOC AI stock forecast should be read as scenario analysis, not a guaranteed target. Using a July 8, 2026 data cutoff, a $21.93 price, and a 2026 FFO-style per-share cash earnings proxy near $1.73, the tested three-year range is roughly $17 in a bearish case, $24 in a base case, and $29 in a bullish case before dividends.
Base case
$23 to $24
More likely if FFO per share grows low single digits, the dividend remains covered, and DOC holds a mid-teens FFO multiple without a major rate shock.
Bearish case
$16.50 to $18
More likely if rates stay high, lab leasing weakens again, tenant credit losses rise, equity-funded growth becomes dilutive, or Janus Living trades below implied value.
DOC AI technical analysis
DOC AI Technical Analysis
DOC AI technical analysis is constructive but late-cycle in the short term. Around the July 8, 2026 data cutoff, DOC traded near $21.93, close to a 52-week high near $22.12. The stock was above cited 50-day and 200-day moving averages, but momentum readings were elevated enough to make breakout entries more sensitive to reversals.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $21.93 | Recent market data around the July 8, 2026 cutoff, cross-checked against Google Finance and MarketWatch reporting. |
| Near support | $21.00 to $21.30 | Approximate 50-day moving average and recent consolidation area. A clean close below this zone would cool near-term momentum. |
| Secondary support | $19.75 to $20.35 | Prior breakout and round-number support zone. A move here would test whether buyers still value the dividend and REIT recovery setup. |
| Near resistance | $22.10 to $22.50 | The stock is near its recent 52-week high area. A failed breakout can create short-term mean reversion risk. |
| 50-day moving average | About $21.27 | Investing.com cited DOC 50-day moving average near $21.27, which puts price modestly above trend support. |
| 200-day moving average | About $20.82 | Investing.com cited DOC 200-day moving average near $20.82, keeping the medium-term trend constructive. |
| Momentum | RSI about 71.6 | An elevated RSI suggests strong momentum but less forgiving entry risk if price fails near resistance. |
| Volume and volatility | Avg. volume about 8.88M, beta 1.05 | Liquidity is ample for a large REIT, while rate-sensitive volatility can still expand around Fed or credit-market news. |
| Invalidation | Close below $20.35 | A decisive break below the prior support zone would invalidate the short-term bullish technical setup. |
DOC AI trading strategy
DOC AI Trading Strategy Framework
The DOC AI trading strategy below is a research framework for planning, not personal investment advice. It combines REIT fundamentals, rate sensitivity, dividend coverage, and technical confirmation.
Trend-following setup
Watch for DOC to hold above the 50-day moving average and break the $22.10 to $22.50 resistance zone on strong volume while REIT rates and credit spreads remain supportive.
Define the invalidation level before entry. A close back below $21.00 or a reversal under the 50-day moving average would weaken the breakout case.
Mean-reversion setup
If DOC pulls back toward $20.00 to $20.35 without a dividend, FFO, or balance sheet thesis break, compare the yield, AFFO coverage, and next earnings guidance before assuming value.
Avoid treating yield alone as downside protection. A close below $20.35 can signal that rate or property-level risk is dominating the income case.
Fundamental monitor
Track FFO as Adjusted, AFFO, net debt to Adjusted EBITDAre, outpatient medical renewal spreads, lab occupancy, Janus Living valuation, share repurchases, and dividend coverage.
Re-run the scenario range after earnings, guidance updates, credit rating changes, or a major move in Treasury yields.
Investment research summary
Four-master Research Compression
Business essence
Healthpeak rents specialized healthcare real estate to providers, life science tenants, and senior housing-related operators. Customers pay because location, compliance-ready space, medical campus access, and operational continuity matter more than generic office space.
Moat
The moat is asset-specific. Campus locations, healthcare relationships, scale purchasing, property operations, and specialized lab and medical infrastructure create friction, but tenant bargaining power and capital costs limit pricing power.
Munger risk inversion
The thesis fails if high rates keep the cost of capital above property returns, lab demand weakens, tenant credit deteriorates, development returns disappoint, or Janus Living adds volatility without enough cash flow.
Management
Management has emphasized portfolio simplification, Physicians Realty integration, outpatient medical leasing, Janus Living formation, Blackstone capital recycling, and share repurchases. The key test is whether these moves grow per-share FFO instead of only asset size.
Industry trend
Healthcare delivery, outpatient care, aging demographics, and medical research support long-term demand. The lab cycle is less certain because biopharma funding and new supply can swing sharply.
Valuation and margin of safety
At about $21.93, DOC is not distressed. Margin of safety depends on durable FFO, dividend coverage, lower capital costs, and whether private market values validate the public market price.
Source-backed data
DOC Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| DOC price | $21.93 | MarketWatch market report and Google Finance quote data | July 8, 2026 |
| Market capitalization | $15.12 billion, verified from $21.93 x 689.42 million shares | Google Finance and financial_rigor.py | July 8, 2026 |
| Shares outstanding | 689.42 million shares | Google Finance, cross-checked with WallStreetZen | July 8, 2026 |
| FY2025 revenue | $2.82 billion | Healthpeak Q4 2025 release, cross-checked with StockAnalysis | July 8, 2026 |
| FY2025 net income applicable to common shares | $70.513 million | Healthpeak Q4 2025 release, cross-checked with StockAnalysis | July 8, 2026 |
| Q1 2026 FFO as Adjusted | $0.45 per share | Healthpeak Q1 2026 earnings release | July 8, 2026 |
| 2026 FFO as Adjusted guidance | $1.71 to $1.75 per share | Healthpeak Q1 2026 earnings release | July 8, 2026 |
| Cash and cash equivalents | $1.171 billion at March 31, 2026 | Healthpeak Q1 2026 release, cross-checked with Seeking Alpha capital structure data | July 8, 2026 |
| Dividend rate | $1.22 annualized, about 5.56% yield at $21.93 | Healthpeak Q1 2026 dividend declaration and Google Finance | July 8, 2026 |
| Net debt to Adjusted EBITDAre | 5.4x for Q1 2026 | Healthpeak Q1 2026 earnings release | July 8, 2026 |
Frequently Asked Questions
View the AI Stock PickerExplore real estate stock screensBuild an AI trading strategyRead the EQIX AI stock analysis
This DOC AI stock analysis is an informational research tool only. It is not investment advice, tax advice, or a recommendation to buy, sell, or hold Healthpeak Properties stock. Forecast scenarios are based on available public data, valuation assumptions, and technical levels as of the stated cutoff date and can be wrong.